<?php die("Access Denied"); ?>#x#a:5:{s:4:"body";s:1469:"

<div class="item-page clearfix">


<!-- Article -->
<article itemscope itemtype="http://schema.org/Article">
	<meta itemprop="inLanguage" content="en-GB" />


<!-- Aside -->
<!-- //Aside -->




	

	

	
	
	<section class="article-content clearfix" itemprop="articleBody">
		<p>Persivia provides hospitals with actionable information to improve clinical, financial and operational performance. By identifying clinical interventions, forecasting revenue, and segmenting patient populations, we are able to help hospitals streamline their operations, mitigate risks, and improve quality of care for patients.</p>
<p>Our solution combines claims-based risk stratification with clinically-rich care gap analyses. This allows us to not only identify high-risk patients, but also uncover those patients within the high strata that have the most actionable clinical opportunities for improvement.</p>
<h4>Persivia is the Solution for Risk Management and Population Analytics:   </h4>
<ul>
<li>Identifies high-risk patients</li>
<li>Calculates Evidence-Based Care Gap Scores (EBCG)</li>
<li>Provides custom treatment plan based on EBCG score</li>
<li>Analyzes PCMH and ACO reimbursements on Hierarchical Condition Categories (HCCs)</li>
<li>Displays real-time alerts for missing and insufficient HCC codes</li>
<li>Longitudinally tracks high-risk groups</li>
</ul>	</section>
	
  <!-- footer -->
    <!-- //footer -->

	
	
	
</article>
<!-- //Article -->


</div>";s:4:"head";a:11:{s:5:"title";s:19:"Persivia - Persivia";s:11:"description";N;s:4:"link";s:0:"";s:8:"metaTags";a:2:{s:10:"http-equiv";a:1:{s:12:"content-type";s:24:"text/html; charset=utf-8";}s:8:"standard";a:2:{s:8:"keywords";s:126:"clinical decision support medication management infection control population health management quality healthcare chronic care";s:6:"rights";N;}}s:5:"links";a:1:{s:60:"http://persivia.com/component/content/?id=234&amp;Itemid=848";a:3:{s:8:"relation";s:9:"canonical";s:7:"relType";s:3:"rel";s:7:"attribs";a:0:{}}}s:11:"styleSheets";a:1:{s:53:"/plugins/content/jadisqus_debate_echo/asset/style.css";a:3:{s:4:"mime";s:8:"text/css";s:5:"media";N;s:7:"attribs";a:0:{}}}s:5:"style";a:0:{}s:7:"scripts";a:8:{s:33:"/media/system/js/mootools-core.js";a:3:{s:4:"mime";s:15:"text/javascript";s:5:"defer";b:0;s:5:"async";b:0;}s:24:"/media/system/js/core.js";a:3:{s:4:"mime";s:15:"text/javascript";s:5:"defer";b:0;s:5:"async";b:0;}s:33:"/media/system/js/mootools-more.js";a:3:{s:4:"mime";s:15:"text/javascript";s:5:"defer";b:0;s:5:"async";b:0;}s:27:"/media/jui/js/jquery.min.js";a:3:{s:4:"mime";s:15:"text/javascript";s:5:"defer";b:0;s:5:"async";b:0;}s:34:"/media/jui/js/jquery-noconflict.js";a:3:{s:4:"mime";s:15:"text/javascript";s:5:"defer";b:0;s:5:"async";b:0;}s:35:"/media/jui/js/jquery-migrate.min.js";a:3:{s:4:"mime";s:15:"text/javascript";s:5:"defer";b:0;s:5:"async";b:0;}s:27:"/media/system/js/caption.js";a:3:{s:4:"mime";s:15:"text/javascript";s:5:"defer";b:0;s:5:"async";b:0;}s:30:"/media/jui/js/bootstrap.min.js";a:3:{s:4:"mime";s:15:"text/javascript";s:5:"defer";b:0;s:5:"async";b:0;}}s:6:"script";a:1:{s:15:"text/javascript";s:576:"
var disqus_shortname = 'jademo-light';
var disqus_config = function(){
	this.language = 'en';
};
window.addEvent('load', function(){
	(function () {
	  var s = document.createElement('script'); s.async = true;
	  s.src = '//jademo-light.disqus.com/count.js';
	  (document.getElementsByTagName('head')[0] || document.getElementsByTagName('body')[0]).appendChild(s);
	}());
});
jQuery(window).on('load',  function() {
				new JCaption('img.caption');
			});jQuery(document).ready(function(){
	jQuery('.hasTooltip').tooltip({"html": true,"container": "body"});
});";}s:6:"custom";a:0:{}s:10:"scriptText";a:0:{}}s:13:"mime_encoding";s:9:"text/html";s:7:"pathway";a:0:{}s:6:"module";a:0:{}}